The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: -0.01 (-5.41%)
Spread: 0.01 (5.882%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

Fri, 12th Nov 2021 12:11

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

----------

Princess Private Equity Holding Ltd - Guernsey-domiciled investment holding company aiming for long-term capital growth and dividend income - Sells stake in Pacific Bells, the fifth-largest franchisee of the Taco Bell brand in the US, to Orangewood Partners. Deal values company's stake in Pacific Bells at about USD18.6 million, up slightly from carrying value of USD18.4 million at September 30.

----------

Civitas Social Housing PLC - social housing investor - Notes, alongside, Triple Point Social Housing REIT PLC, that Falcon Housing Association CIC gets notice from Regulator of Social Housing. Falcon has not received a grading as it leases fewer than 1,000 homes. "Falcon has committed to continue to engage with the RSH and in turn CSH will continue its supportive relationship with Falcon and all other counterparties with the shared objective of further enhancing standards across the sector and encouraging APs to demonstrate their independence and self-reliance," company says. Falcon represents 19.9% of Civitas's rent roll, while it is 10% of Triple Point's current portfolio.

----------

Northern Bear PLC - Newcastle Upon Tyne-based specialist building and support services company - Says it has traded well in the first half of its current financial year, ended September 30, and expects to report operating profit in the range of GBP1.4 million to GBP1.5 million, up from GBP500,000 a year prior. Operating profit for the six months to September 30 would also represent an increase on the pre-Covid comparative of GBP1.4 million. Looking ahead, the company says its forward order book remains strong and should support its trading performance in the coming months. Chair Jeff Baryshnik says: "We are pleased to announce strong expected operating results for H1 FY22, despite ongoing industry-wide challenges."

----------

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Files a new patent application in relation to NXP004. This filing covers a new family of co-crystalline forms of an undisclosed marketed drug that is approved globally for the treatment of several cancers. This is the second patent application related to NXP004 that Nuformix has filed and it complements the previous patent application on NXP004 co-crystals.

----------

Creo Medical Group PLC - medical device company focused on surgical endoscopy - Acquires UK-based manufacturer and designer of power amplifiers and radio frequency products Aber Electronics Ltd for an unidentified sum of fixed cash consideration, plus a contingent consideration over three years. "Creo is an existing customer of Aber, using its products within the CROMA Advanced Energy Platform. This acquisition will complement Creo's research, design and manufacturing processes, provide additional specialist microwave and radio frequency capability and expertise within the business and enhance a key element of the group's supply chain," company says.

----------

Microsaic Systems PLC - Surrey, England-based mass spectrometry instruments for pharmaceutical industry - Launches new compact screening platform technology capability to its platform, as company continues to make strategic transition from equipment only sales to remote detection and analysis of human diagnostics and environmental health monitoring. New platform expected to launch in first half of 2022. Company adds: "The latest addition to Microsaic's platform is the integration of the Company's compact MS technology with Gas Chromatography and extends Microsaic's existing applications in Liquid Chromatography. This combination will provide an extensive range of analysis required by end-users for chemical detection, for use in a combined market estimated to be worth over USD1 billion."

----------

600 Group PLC - West Yorkshire, England-based manufacturer and distributor of machine tools, precision engineered components and industrial laser systems - Says its three US operations have been granted forgiveness of their second round loans under the US government paycheck protection program which in total amounts to USD2.2 million. Turning to trading, the company says it performs in line with expectations and order intake has continued to improve during the current financial year. The forward order book stands at USD23 million as at November 9, as increase when compared to the same date one year earlier, when order book was USD11 million.

----------

Powerhouse Energy Group PLC- technology company commercialising hydrogen production from waste plastic - Says its development partner Hydrogen Utopia International PLC has signed a framework agreement with Linde PLC's Engineering unit. The framework agreement provides Linde Engineering with a five year exclusivity to supply Hydrogen Utopia in its development of Powerhouse DMG technology particularly in Poland, Hungary and Greece. The Powerhouse DMG process can generate up to 2 tonnes of road-fuel hydrogen and more than 58 megawatt hours of exportable electricity per day. The project, if completed, is expected to contain ten DMG units in one geographical area.

----------

Blencowe Resources PLC - miner focused on developing the Orom-Cross graphite project in Uganda - Completes an over-subscribed capital raise for GBP2 million at 5p each through the issue of 40.0 million new shares. This includes a subscription of GBP75,000 from the directors and chief executive. These funds will be used for the further development of the mineral exploration and development company's flagship Orom-Cross graphite project in Uganda.

----------

PetroNeft Resources PLC - oil & gas exploration and production company - Says it is extending the campaign in the Tomsk Oblast, Russia, for upcoming winter with the goal of increasing production and also improving the sustained flow rate of existing wells over two producing fields in licence 61. During the first quarter of 2021, a two well fracking program was successfully completed on wells S-373 and L-115. Both were highly successful and exceeded expectations . As a result, PetroNeft signs a contract with NewTech Well Services LLC, an oilfield services company, for the provision of a larger fracking program covering an additional five wells.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
28 Jul 2022 16:14

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

Read more
28 Jul 2022 15:01

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2022 12:25

IN BRIEF: Nuformix shares rise as progresses with cancer programme

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."

Read more
27 Jun 2022 21:51

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
31 May 2022 12:41

Nuformix Executive Chair Alastair Riddell resigns after one year

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Read more
30 May 2022 11:54

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.

Read more
30 May 2022 11:13

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

Read more
28 Mar 2022 19:18

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.

Read more
8 Feb 2022 13:58

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Read more
8 Feb 2022 10:52

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

Read more
14 Dec 2021 18:01

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Read more
25 Nov 2021 16:23

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

Read more
12 Nov 2021 10:54

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

Read more
9 Nov 2021 15:30

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.